By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: NEOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Neogen Corporation – NEOG
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Technology > NEOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Neogen Corporation – NEOG
NEOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF 0,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Neogen Corporation – NEOG
Technology

NEOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Neogen Corporation – NEOG

GlobeNews Wire
Last updated: 04/09/2025 6:37 AM
GlobeNews Wire
Published: 04/09/2025
Share
SHARE

NEW ORLEANS, Sept. 03, 2025 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 16, 2025 to file lead plaintiff applications in a securities class action lawsuit against Neogen Corporation (NasdaqGS: NEOG), if they purchased the Company’s shares between January 5, 2023 through June 3, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Michigan.

Get Help

Neogen investors should visit us at https://claimsfiler.com/cases/nasdaq-neog/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Neogen and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On April 9, 2025, the Company disclosed a quarterly revenue decrease of 3.4% to $221 million due to integration issues and again cut its FY25 guidance and noted that capital expenditures were expected to be $100 million as a result of lowered adjusted EBITDA and a pull-forward of integration-related capital expenditures into FY25, as well as announcing the departure of its CEO. On this news, the price of Neogen’s shares plummeted 28% to close at $5.02 per share, on a volume of 47 million shares. Then, on June 4, 2025, the Company disclosed that it expected “EBITDA margin to probably be around the high-teens” which represented a considerable drop from the previous quarter’s profit margin of 22%. On this news, the price of Neogen’s shares fell an additional 17%, to close at $4.96 per share.

The case is Operating Eng’rs Constr. Indus. & Misc. Pension Fund v. Neogen Corp., et al., No. 25-cv-00802.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

Robert Lewandowski Named Global Brand Ambassador for KSM-66 Ashwagandha
Automobili Lamborghini inaugurates its new Selleria alongside transformed Revuelto and Temerario production line
Monthly information on share capital and company voting rights
Fibe empowers 2 lakh individuals to upskill through its financing solution, signs its 500th partnership with JAIN Online to expand access to affordable higher education
BlueWillow Biologics Intranasal Bird Flu Vaccine Shows Signs of Broad Immune Response in Phase I Clinical Trial Published in Nature Communications
TAGGED:100,000actionAdventureagainstalert:claimsfilerclasscorporation:deadlineexcessinvestorslawsuitsleadlossesneogneogennewsplaintiffremindsshareholderwith
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
OpenLight Raises M Series A to Scale Next-Gen Integrated Photonics for AI Data Centers
News

OpenLight Raises $34M Series A to Scale Next-Gen Integrated Photonics for AI Data Centers

27/08/2025
Siemens Healthineers Receives Frost & Sullivan’s 2025 North America Company of the Year Award for Excellence in Advanced Visualization Applications
Limited Drop, Maximum Flex: Cleveland Golf and SWAG Partner for RTZ Wedge Collaboration
NEW RESEARCH: Kemira Water Index 2025 exposes critical weaknesses in water resilience and alarming consumer unpreparedness
Bybit Becomes First Crypto Exchange to Partner with QNB Group and DMZ Finance to Accept QCDT, Unlocking Institutional Access to Digital Assets
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?